Addition of Insulin Pump & CGM data , used for intensive glucose management of Type 1 and Type 2 diabetes, enhances utility of Glooko’s remote monitoring and predictive glucose analytics tools for high-risk diabetes patients and their healthcare providers .
Palo Alto, Calif. – June 3 , 2015 – Glooko Inc. today announced it will demonstrate its integration with Insulin Pumps and Continuous Glucose Monitors (CGMs) at the American Diabetes Association’s 75 th Scientific Sessions , adding to the diabetes population management platform’s existing support for 30+ blood glucose meters, popular activity trackers, and biometric monitors for blood pressure and weight . Glooko’s presence at the conference, occurring June 4-8, 2015 in Boston, MA, will include a presentation at the Insulet booth as well. Glooko will demonstrate it’s end-to-end platform at booth #104.
Glooko’s integration with insulin pumps and CGMs meets the growing demand from ACOs and progressive health system s for on-demand, remote access to diabetes data associated with the significant subset of their diabetes population requiring regular glucose monitoring and tight regulation of insulin levels. According to The Diabetes Device Market Outlook to 2016 published by Business Insights, insulin pumps, which deliver rapid-acting insulin 24 hours a day through a catheter placed under the skin, are used by 33% of people with Type 1 diabetes , while CGMs, used to measure glucose levels in real-time throughout the day and night, are expected to be used by up to 25% of people with Type 1 diabetes in 2016. The study indicates that t he projected market valuation associated with the se diabetes devices in 2016 is $2.9B and $763M, respectively.
“Utilizing Glooko’s remote monitoring functionality, ACOs and health systems can access risk-stratified patient data on-demand after a patient syncs his or her diabetes device to a smartphone ,” said Rick Altinger, Glooko’s CEO. He continued, “With Glooko’s addition of Pumps and CGMs, care teams can better track and manage people who are starting or continuing intensive insulin therapy to improve their overall care which may ultimately improve their health outcomes.”
In conjunction with supporting Insulin Pumps and CGMs, Glooko has added the ‘Pump Day View’ and ‘Pump Insights’ as new functionality to its platform. The ‘Pump Day View’ will allow seamless correlation amongst a patient’s basal and bolus insulin records, carb intake, exercise, and glucose readings from the patient’s CGM or blood glucose meter. The ‘Pump Insights/Settings’ view provides clarity on the impact of pump suspends, temporary basal events, and site changes on blood glucose levels. By leveraging Glooko’s diabetes device agnostic approach, ACOs, health systems, and people with diabetes can visualize data from their preferred combination of insulin pumps, CGMs, blood glucose meters, and fitness trackers in Glooko’s standardized, best-in-class diabetes data views.
In conjunction with the ADA conference, Glooko will be presenting at The DiabetesMine D-Date Exchange meeting on Friday, June 5th, held at the Cambridge Innovation Center. The company will also be sponsoring the 9th Annual ADA Forum, hosted by diaTribe and TCOYD, at the Seaport Boston Hotel on Monday, June8th.
About Glooko, Inc.
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application, which aims to improve health outcomes for people with diabetes, which may in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 4 0 blood glucose meters, pumps (coming soon or currently in the design phase), CGMs (coming soon or currently in the design phase), fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko.
For More Information
Vikram Singh
Glooko PR
[email protected]
Leverages recent investment to fuel expansion of its Unified Platform for Diabetes Management by continuing to add data from diabetes devices
Palo Alto, Calif. – June 3, 2015 – Glooko Inc. today announced partnerships with Dexcom, Inc., developer and marketer of a continuous glucose monitoring (CGM) system, and with Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System. These partnerships are another step in Glooko’s efforts to unify all diabetes relevant device data into a single, unified platform to enable both patients and healthcare providers to improve health outcomes.
“Digital health data integration will have a significant impact on the clinical care we provide for people with diabetes,” said Dr. Howard Wolpert of the Joslin Diabetes Center.” Our work with Glooko in creating the Joslin HypoMap powered y Glooko and Glooko continuing to add in device data and reports that synthesize information to provide clinically significant insights not present on currently-available data downloads will help more patients to realize the benefits of CGM and pump therapy, and will help clinicians provide more efficient and effective care,” he continued.
Glooko will deliver its next generation product that includes both Dexcom CGM and Insulet’s OmniPod pump data this summer, adding data from both systems into it’s unified platform that already syncs data from more than 30 blood glucose (BG) monitors (over 90% market share) and the most popular fitness and biometric tools with patient’s Apple or Android mobile devices. Patients can also record food intake and medication and insulin dosage to provide context around changes in their blood glucose readings.
“We are pleased to be partnering with Glooko to add Dexcom CGM data to their comprehensive diabetes management platform,” said Kevin Sayer, CEO of Dexcom. “We believe that Glooko’s platform which accesses Dexcom data through our ‘open architecture’ can be a very meaningful tool for our patients to manage their diabetes.”
Dexcom’s CGM data and Insulet’s OmniPod’s pump data will be brought into Glooko and structured for patients and their healthcare providers in a simple to interpret view in both the Glooko mobile app and in a risk-stratified view via Glooko’s Population Tracker™. Glooko will access data from these devices directly, in addition to pulling data from the Apple Healthkit. Glooko enables healthcare providers to engage at-risk patients before costly intervention and hospitalizations occur. In addition, Glooko allows healthcare providers and patients to understand and analyze their diabetes data, and set reminders for improved treatment plan adherence.
“Now OmniPod patients will have the ability to view their insulin delivery, blood glucose and CGM data together,” said Patrick Sullivan, President and Chief Executive Officer of Insulet Corporation. “Patients will have access to data that will allow them to take full advantage of the clinical benefits that the OmniPod system provides while still providing the freedom of the unique, tubeless insulin delivery system. This collaboration furthers our shared vision of helping to make life with diabetes easier by providing greater access to the data people living with diabetes need to make smart and effective decisions to realize better control.”
This announcement comes on the heels of Glooko’s recent Series B investment that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of Glooko’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.
Glooko is demonstrating its integration with both the Dexcom CGM and the Insulet OmniPod Insulin Management System in booth #104 at the American Diabetes Association’s Annual Scientific Conference from June 5 – 9 at the Boston Convention and Exhibition Center in Boston, MA. They are scheduled to release the integrated product for public consumption later in the summer o f 2015.
About Glooko , Inc.
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application, which aims to improve health outcomes for people with diabetes, which may in turn reduce costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, pumps, CGMs, fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to patients, health systems and payers, as well as, third party developers . Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko .
About Dexcom , Inc.
DexCom, Inc., ( NASDAQ: DXCM ) headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers in the hospital. For more information visit: http://dexcom.com/
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod® Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet’ s subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit Insulet’s customer blog, Suite D: http://suited.myomnipod.com . Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.For more information, please visit: http://www.myomnipod.com .
For More Information
Vikram Singh
Glooko PR
[email protected]
Diabetes management platform leverages recent investment to grow leadership bench with experienced executives
Palo Alto, Calif. – April 23, 2015 – Glooko Inc., the leading unified platform for diabetes management, today announced the addition of two new executives to its management team. Serdar Akin joins as Vice President of Development and Michelle de Haaff joins as Vice President of Marketing and Customer Success. Both executives come on-board with years of experience in product delivery, marketing and customer experience.
Serdar joins Glooko after 15 years in executive roles at Symantec’s Global Enterprise Security Group and at Intuit Health where he led product management and user experience design. He oversaw a portfolio of products that served over 60,000 healthcare providers and 7 million patients. Mr. Akin was a principal driver behind expanding Intuit’s healthcare focus to include healthcare provider services. This effort resulted in the acquisition of Medfusion, the leading supplier of patient-healthcare provider communication and portal services. At Glooko, Serdar will lead the product management and development team and will focus on continuing to expand the Glooko Unified Platform to include additional device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.
“Glooko is at a unique time of strong growth and increasing patient and provider engagement,” said Mr. Akin. “I am excited to lead the development team towards continuing to deliver a secure, scalable and intuitive software platform that can improve the lives of people with diabetes and provide management and remote monitoring tools for their care team.”
Michelle joins Glooko after 18 years spent in the customer experience and analytics software industry. She recently came to Glooko from Medallia, an enterprise customer experience SaaS company where she led marketing globally through Medallia’s explosive market growth. Prior to Medallia she led the product, marketing and customer engagement teams at Attensity Software, a SaaS text analytics company. She also led product management at Blue Martini Software, an eCommerce and web analytics company, from its early years through its IPO. Prior, she was a CRM practice leader with Ernst and Young Management Consulting. Her expertise is in the cross section of analytics and customer engagement. Michelle is a passionate and proven leader in the practice of creating customer success. At Glooko, she is building a Glooko customer success team that is focused on ensuring that Glooko’s customers – both patients and healthcare providers – have the optimal customer experience using Glooko.
“I believe Glooko will have impact at a global scale. Millions of people with diabetes and their healthcare providers will have the data and insights they need to make better daily decisions about personal lifestyle choices,” Michelle explained. “Additionally, Glooko is hitting an inflection point – where healthcare doesn’t just happen when a person visits the doctor or is hospitalized, but instead happens 24x7x365 and leverages on-demand data to proactively improve overall health outcomes,” she noted.
“We are collectively very happy about the new energy, ideas, skills and ‘roll up their sleeves’ attitude that both Serdar and Michelle bring to Glooko,” said Rick Altinger, CEO of Glooko. “Serdar’s background in product delivery combined with Michelle’s ability to empathize with and create great customer experiences will take Glooko to the next level in our ability to make diabetes management easier for both patients and their care team,” continued Rick.
This announcement comes on the heels of Glooko’s recent Series B investment that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of Glooko’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.
About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko.
Contact:
Vikram Singh
[email protected]
925-487-1461
Investment to Fuel Expansion of Diabetes Device Integrations and Clinical Applications Built on Leading Mobile and Population Diabetes Management Platform
Palo Alto, Calif. – March 17 , 2015 – Glooko Inc. today announced that it has raised $16.5 Million in Series B financing. The funds will be used to expand the company’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms. Canaan Partners and Medtronic joined existing investors including The Social + Capital Partnership and Samsung in the financing. As part of this round, Canaan Partners’ Wende Hutton has joined the Glooko Board of Directors.
“The healthcare industry is at an inflection point with the advent of the Affordable Healthcare Act and increased demand for better quality care without raising costs. Companies that are able to offer unprecedented access to actionable patient information combined with intuitive mobile applications are poised to meet those demands,” noted Wende Hutton, General Partner at Canaan Partners. “Glooko is the perfect example of a company that goes beyond developing a simple wearable or mobile phone app they have delivered a solution that improves patient outcomes by engaging both patients and their healthcare providers to more easily manage and gain insights from the often complex web of diabetes devices.”
Glooko’s unified diabetes management platform enables patients to better manage their diabetes and their healthcare providers to proactively engage their diabetes populations via a mobile, cloud-based platform. Using Glooko’s bluetooth-enabled MeterSync device, patients are already able to sync data from more than 30 blood glucose monitors (over 90% market share) with their Apple or Android mobile device. This data is then structured for providers in a simple to interpret, risk-stratified view via Glooko’s Population Tracker™, a population management tool, and via integration into other platforms, such as an Electronic Health Record (EHR). Glooko allows healthcare providers to engage at-risk patients before costly intervention and hospitalizations occur. In addition, Glooko allows healthcare providers and patients to create reminders for improved treatment plan adherence, integrate data from popular fitness trackers and biometric tools, and allow patients to record food intake and insulin dosage to provide context around changes in their blood glucose readings.
Glooko has already partnered with leaders in diabetes care, including the globally renowned Joslin Diabetes Center, and US care leaders such as the Diabetes & Glandular Disease Clinic (DGD) and Atrius Health, to name a few. Providers, health systems and payers can currently track patient progress, proactively manage and take action with at-risk patients and drive intervention programs with Glooko. By adding data from insulin pumps, continuous glucose monitoring systems and integrating personalized predictive algorithms in to its platform, Glooko will bring more utility to patients who require intensive, day-to-day glucose management, and make it easier for healthcare providers to get a full picture of a patient’s health so they can proactively treat them.
“Glooko has taken the power of mobile, cloud and analytics innovation to deliver an application that has real, daily use in helping improve the health of patients with diabetes,” said Rick Altinger, CEO of Glooko. “We have successfully attracted partnerships and investments from leaders in diabetes healthcare to join our mission in creating easy-to-use and intelligent software that adds utility for patients, healthcare providers, pharmaceutical companies and payers. The new investment will further bolster our leadership position in this area.”
About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system . Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc, and Facebook.com/Glooko.
About Canaan Partners
Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management and over 160 exits to date, Canaan has funded some of the world’s leading technology companies. Recent exits include Len ding Club, Ebates, and Skybox Imaging, as well as healthcare stars like Chimerix, Durata Therapeutics and Civitas Therapeutics. Current technology investments include Cardlytics, Instacart, Kabam and SOASTA, and current healthcare investments include Arvin as, CytomX, ChronoThera and Truveris.
For more info, visit canaan.com.
Contacts
Vikram Singh
[email protected]
925-487-1461
Carolyn Hawley
[email protected]
619-849-5375
Palo Alto, Calif – Nov 12th, 2014 – Glooko Inc., announced today the integration of activity, weight and blood pressure data from leading wearable activity and biometric trackers into its mobile, software as a service (SaaS) diabetes remote monitoring and population management platform. For the first time, data from fitness monitors including Fitbit, iHealth, Jawbone, Moves, RunKeeper, Strava, and Withings can be correlated and visualized against the verified blood glucose readings that Glooko currently liberates from more than 30 popular blood glucose meters using its MeterSync™ Blue technology.
With this latest innovation Glooko addresses the long-standing challenge faced by patients with diabetes of monitoring physical activity and food intake, in addition to their blood glucose levels, all of which are paramount to diabetes and chronic disease management. Physical activity has a significant impact on a patient’s blood glucose level so now patients and their care team will more clearly see the cause and effect relationship between the two. Traditional mHealth solutions requiring manual entry of this data have struggled to deliver the accuracy required for health systems and payer groups to cost – effectively engage their diabetes populations. Glooko builds on its device-agnostic platform focused on data accessibility and advanced analytics for diabetes management.
“Physical activity is one of the major causes of hypoglycemia in individuals with diabetes. Daytime exercise will often have a delayed effect on the glucose levels and lead to nighttime hypoglycemia,” said Howard Wolpert, MD, Director of the Joslin Institute of Technology Translation. “The integration of activity data from wearable devices into the Glooko-Joslin HypoMap system will help individual patients identify their own individual specific activity threshold that is predictive of overnight lows. We will be able to provide patients with alerts when they reach their hypoglycemia risk threshold, so that they can take preemptive steps – such as adjusting their insulin doses or eating a snack – to prevent hypoglycemia. This is one of the first steps in our vision of building a diabetes care ecosystem that will provide remote, intelligent, 24-7 guidance to patients with diabetes everywhere.”
“Access to biometric data like activity and blood pressure means our platform can be used to correlate blood glucose to lifestyle behavior to a degree not previously possible,” added Rick Altinger, Glooko CEO. “In the future, Glooko intends to use physician prescriptions to drive algorithms that utilize a patient’s level of activity along with retrospective glucose levels to make medication and insulin adjustment recommendations.”
About Glooko Inc.
Glooko is an innovative Silicon Valley company that delivers a FDA-cleared, HIPAA-compliant SaaS and mobile platform designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management platform includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes-centric analytics and supplies standardized reports, risk flags and insights to health systems and payers via API’s and web-based tools.
Glooko was founded in 2011 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch
Palo Alto, Calif. – October 2nd, 2014 – Glooko Inc., announced today the launch of Glooko MeterSync Blue, strengthening its position as the industry leader in delivering a mobile, software as a service (SaaS) diabetes remote monitoring and population management platform. Now patients can utilize Bluetooth to connect any of more than 30 popular blood glucose meters to the Glooko platform on Android or Apple devices, as an easier alternative to a physical connection with the current Glooko MeterSync cable.
With the addition of the Glooko MeterSync Blue – featuring Bluetooth Smart™ and Glooko’s FDA-cleared technology-the company’s diabetes management platform provides health systems and payer groups the ability to more cost-effectively enroll diabetes patients into remote monitoring programs without the need for patients to switch to costly, wireless-enabled, blood glucose meters developed specifically for telemedicine. Instead, health systems and payer groups can leverage the tens of millions of meters already deployed to patients worldwide.
“Glooko’s ability to sync blood glucose data from several meters and analyze trends has added efficiency within my clinical practice”, said renowned endocrinologist Dr. Zachary Bloomgarden, Clinical Professor at Mt. Sinai Medical Center. “I am looking forward to using Glooko MeterSync Blue, which should make the platform more valuable by ensuring that patients can more seamlessly share their data with me between visits, particularly those at higher risk, including women during pregnancy and poorly controlled patients initiating treatment with insulin. It should also help with patients who are not at high risk but for whom the ability to review home glucose monitoring results will improve adherence to the increasingly complex regimens of modern diabetes management.
“Glooko facilitates remote monitoring with the Glooko Population Tracker, which delivers pattern recognition algorithms and flags for care managers to easily identify patients experiencing potentially harmful amounts of hyperglycemic (high blood glucose) or hypoglycemic (low blood glucose) events in between clinic visits. By allowing patients to wirelessly sync each blood glucose reading after testing, the MeterSync Blue opens the door for Glooko, in collaboration with health systems and payers, to deliver more real-time reminders and recommendations to patients with diabetes.
For example, Glooko and the Joslin Diabetes Center recently deployed ‘Joslin HypoMap™’ that relies on timely blood glucose data to enable providers and patients to better manage hypoglycemia, which is the predominant cause of hospitalizations for patients with diabetes.
About Glooko Inc.
Glooko is an innovative Silicon Valley company that delivers a FDA-cleared, HIPAA-complaint SaaS and mobile platform designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management platform includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes - centric analytics and supplies standardized reports, risk flags and insights to health systems and payers via API’s and web-based tools.
Glooko was founded in 2011 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is Chief Medical Officer. In addition to the founders, investors include Samsung Ven ture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch.
(Boston, Massachusetts and Palo Alto, California) June 11 , 2014 – Joslin Institute for Technology Translation (JITT) at Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc., a mobile, cloud based diabetes management system announced the release of their jointly developed Joslin HypoMap™ powered by Glooko™. Joslin HypoMap, powered by Glooko, is designed to improve health outcomes and reduce costs for use by patients and providers to improve self-management of hypoglycemia (low blood glucose events) as part of their diabetes management program. The Joslin HypoMap will be launched at the American Diabetes Association’s 74th Scientific Sessions, occurring June 13-17, 2014 in San Francisco. Visit us at booth #2149-Joslin Diabetes Center or #2241-Glooko.
Joslin HypoMap powered by Glooko incorporates a data-driven method to identify individuals with diabetes who have hypoglycemia unawareness, a condition that puts patients at higher risk for dangerous hypoglycemia episodes which can result in serious injury, hospitalization and even death. After experiencing a hypoglycemic event, patients are prompted to record symptoms, perceived causes, and self-treatments in the Joslin HypoMap mobile app. The results are then presented in a standardized, informative set of reports that are available to the patient and the designated patient’s care team. Joslin HypoMap powered by Glooko can be an effective self-management tool providing teachable moments with caregivers when patients miss opportunities to identify, record the symptom and treat a hypoglycemic event. The reports can also graphically present identifiable cyclical patterns related to a patient’s lifestyle habits that may contribute to the development of hypoglycemia.
“Patients rarely have an accurate recollection of the factors leading up to a hypoglycemia episode that occurred months before, and the opportunity to identify underlying causes and, therefore, prevent recurrences is lost,” said Howard Wolpert, MD, Director of the Joslin Institute for Technology Translation. “For the first time, clinicians can have substantive discussions about specific hypoglycemic events using key contextual data such as symptoms, causes, and treatments recorded in real-time, and subsequently help patients to improve their diabetes self-management skills and prevent future episodes.”
According to a study by Gurkirpal Singh, MD, Stanford, which was presented at the 2013 ADA Scientific Sessions, hypoglycemia was seen in a s many as 269,000 US hospitalizations for both Type I and Type 2 patients on insulin. This amounted to nearly $13B in charges in 2009. Joslin HypoMap powered by Glooko aims to create awareness in patients around causes and symptoms that precede their severe hypoglycemic events to provide a future knowledge base to avert possible serious consequences.
“Our partnership with Joslin embodies the transformational capabilities of the Joslin Institute for Technology Translation. In engaging patients and their care team in hypoglycemia awareness through the Joslin HypoMap and our mobile platform, we will jointly contribute to needed advances in diabetes self-management tools” said Rick Altinger, CEO, Glooko. “ By combining Joslin HypoMap with Glooko’s meter-agnostic system, we can improve diabetes patient care while also lowering costs to the overall healthcare system.”
In January, Glooko announced its partnership with Joslin Diabetes Center, a global leader in diabetes care, research and education. The stated purpose of the agreement is to use the Joslin clinical expertise and jointly deploy with Glooko an advanced diabetes technology platform that will allow patients to capture glucose and contextual data to allow for improved self-management tools initially involving hypoglycemia awareness.
Glooko’s FDA 510(k) cleared diabetes management system is available to health systems and payers and is designed to be integrated into EHR’s and other health record systems.
Joslin Diabetes Center does not promote or endorse any product. Revenue and fees from the JITT will be invested in digital health to improve patient care.
About Joslin Institute for Technology Translation (JITT)
Joslin Institute for Technology Translation is focused on leveraging the potential of technology with the introduction of clinical solutions and digital health to improve the lives of people with diabetes. JITT pairs Josli n Diabetes Center’s clinical expertise with industry to enhance the development of new and clinically effective technologies and digital health tools; it is uniquely positioned to provide clinical insight for medical devices, technologies and strategies for cost-efficient solutions that improve diabetes care and outcomes.
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, is committed to advancing diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives a nd offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Its mission is to prevent, treat and cure diabetes and the organization’s vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org .
About Glooko Inc. Glooko is an innovative Silicon Valley company that delivers a mobile and cloud based, diabetes & chronic disease management system designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management system includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes-centric analytics and supplies standardized reports, risk flags and insights to case managers and Providers via API’s and web-based tools.
Glooko was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Ch amath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Vent ures, Judy Estrin, and Dr. Russell Hirsch.
Media Contacts:
Vikram Singh
Glooko
650 - 720 - 5310
[email protected]
Jeff Bright
Joslin Diabetes Center
617 – 309 - 1957
[email protected]
Partners to develop and deploy advanced mobile and web based diabetes management technology and decision 6 support tools for optimal diabetes care
Palo Alto, California & Boston, Massachusetts 7 January 21, 2014 – Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc. have signed an agreement to jointly deploy an advanced diabetes management technology platform that will allow patients to share diabetes management data and in turn use that data through decision 7 making algorithms for optimal and predictive diabetes care. Glooko and Joslin will jointly provide a diabetes management solution globally to health systems, governments and payer groups aiming to improve health outcomes and lower costs.
The agreement allows Joslin Diabetes Center, to create a ‘Virtual Joslin’ service by adding its clinical expertise to Glooko’s innovative diabetes management technology. The Glooko/Joslin service will allow Joslin and other care teams to remotely monitor, coach and guide diabetes patients between their in 7 clinic consultations. The Glooko/Joslin solution will use pattern recognition algorithms to predict when patients are at risk for severe hypoglycemia or other complications and trigger provider interventions before serious complications and costs arise.
“The Glooko/Joslin platform will address a long standing need in diabetes management. The system will engage patients to analyze the factors underlying the fluctuations in their glucose levels and provide prompts to reinforce behavior change and to improve their diabetes self 7 management skills,” said Howard Wolpert , M.D., Director of the Joslin Institute for Technology Translation.
“Glooko’s unique technology gives clinicians the data necessary to close the communication loop with patients in between clinic visits,” said Rick Altinger, Glooko CEO. “Improved data transparency and communication between clinicians and patients can change the way diabetes is managed.”
Glooko offers an FDA 510 (k) cleared diabetes management system focused on making glucose data accessible to both patients and clinicians. The Glooko Diabetes Management System, consisting of the Glooko MeterSync Cable, the engaging Glooko patient mobile application (app) for both iOS and Android, and the Glooko web dashboard, allows glucose data to be downloaded from dozens of meters that are used by tens of millions of people. To download the data, a user must simply connect their glucose meter to their mobile device using the Glooko MeterSync Cable.
From the Glooko app, the glucose data and other key diabetes data like nutrition metrics, exercise, and medication s can be collected and sent to provider 7 accessed web dashboards and EHR’s. This allows healthcare professionals to analyze blood glucose along with other related biometric data, identify at 7 risk patients, and make informed therapeutic decisions. Because the Glooko system works on both iOS and Android mobile operating systems, Glooko currently supports data transfer from 29 glucose meters to dozens of mobile devices.
“We have been watching Glooko closely over the last year as they have been liberating blood glucose data from meters and making it accessible to patients and clinicians for advanced diabetes management,” said John L. Brooks , III, President and CEO of Joslin. “We are excited to work closely with Glooko on the next leap forward to make glucose data actionable. We intend to create a System that will make a significant impact on dramatically improving patient outcomes and lowering costs.”
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.
About Glooko Inc.
Glooko is an innovative Silicon Valley company with a unique diabetes management solution for patients, health systems, and payer groups. Glooko’s products – the Glooko mobile apps , MeterSync Cable for iOS and Android, and the Glooko Web Dashboard – enable clinicians to remotely access their patients’ blood glucose readings and other related data. The company ’s system allows people with diabetes to download their glucose readings to t heir mobile device. The company was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch.
Media Contacts:
Joslin Contact:
Jeffrey Bright
[email protected]
Glooko Contact:
Rita Sharma
[email protected]
$7 Million Round from Investors including Samsung Venture Investment Corporation to ramp up growth with health providers and payer groups
January 8, 201 4 – Glooko Inc., makers of a FDA-cleared mobile diabetes management system , announced today it has raised $7 million in a Series A-1 round from several new investors including Samsung Venture Investment Company (SVIC ) and Lifeforce Ventures as well as existing investors including The Social + Capital Partnership , Sundeep Madra and Yogen Dalal. Using this investment, Glooko will focus on enabling predictive diabetes care by delivering patient data and decision-making algorithms to health providers and payer groups. Samsung Venture Investment brings in strategic value given Samsung ’s leadership position in the mobile market globally.
“Over the last two years, Glooko has built a diabetes management infrastructure bent on liberating blood glucose data from glucose meters and making it accessible to patients and clinicians,” said Rick Altinger, Glooko’s CEO. “Our next steps are to scale Glooko’s system to global accessibility and to add a layer of analytics and messaging capable of making therapeutic recommendations for diabetes management. The investors who have contributed to this round will help us achieve these goals.” Glooko’s existing investors participated in this financing round with a strong vote of confidence in the company’s vision and direction. “We believe that Glooko can fundamentally disrupt the way diabetes is managed here in the US and other parts of the world,” said Chamath Palihapitiya , Founder & Managing Partner, Social + Capital.
Glooko offers an FDA 510(k) cleared diabetes management system focused on making glucose data accessible to both patients and clinicians. The system includes the Glooko MeterSync Cable and Glooko’s mobile application-when combined, these tools allow for glucose data to be directly transferred from a glucose meter into a mobile device. The mobile apps integrate into the existing Glooko diabetes management web dashboards, which enable healthcare professionals and care management teams to remotely monitor and identify at-risk patients.
Glooko is available on both the iOS and Android operating systems – the company received FDA 510(k) clearance for its Android system and launched it in November . Across both mobile operating systems, Glooko currently supports data transfer between 26 glucose meters and 2 7 mobile devices.
By using Glooko’s population management and analytics tools , health systems and disease management organizations can increase focus on at-risk patients and achieve higher level of adherence to treatment plans among their diabetes population . Scripps Whittier Diabetes Institute is amongst notable health systems that are currently using Glooko’s diabetes management system .
To learn more about Glooko’s enterprise-grade diabetes management system, email [email protected]. To reach Glooko’s Press Team, email [email protected].
About Glooko Inc.
Glooko is an innovative Silicon Valley startup with a unique diabetes management solution for patients, health systems, and payer groups. Glooko’s products – the Glooko mobile app, MeterSync Cable for iOS and Android, and Glooko Web Dashboard – enable clinicians to remotely access their patients’ blood glucose readings and related data. The company does so by allowing people with diabetes to download glucose readings to their smartphone. The company was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin , and Dr. Russell Hirsch.
About Samsung Venture Investment Corporation
Samsung Venture Investment Corporation manages investment and investment-related activities for Samsung affiliate companies. The investment mandate for Samsung Venture Investment Corporation tracks closely to the strategic priorities of Samsung affiliate companies’ core operating divisions, and encompasses investments in semiconductors, displays, telecommunications, and consumer electronics
Android Compatible System Cleared by FDA and App Available in the Google Play Store , Device available on Amazon
PALO ALTO, Calif. – October 29 , 2013 – Glooko, Inc., makers of an innovative mobile solution for diabetes management, today announced it has launched an Android – compatible version of its next generation Glooko Diabetes Management System . The Glooko system for Android, consist ing of the mobile app, MeterSync Cable and web dashboards, is the only FDA – cleared mobile diabetes management system that supports the transfer of blood glucose data direct from dozens of compatible glucose meters into many Android devices .
Glooko’s Android app will integrate into the existing Glooko Diabetes Management web dashboards , which enables healthcare professionals to identify at – risk patients, analyze blood glucose levels for patterns and make informed therapeutic decisions . The new product has been cleared by the FDA ’s 510 (k) process.
” Our diabetes management system aims for universal access for people with diabetes across the globe,” said Ri ck Altinger, Glooko CEO. “By leveraging Android’s market reach, we hope that providers , health systems and payers can efficiently manage their diabetes patients, improve outcomes and lower costs. ” In support of Glooko’s market expansion into health systems , the company recently joined the Samsung Enterprise Alliance Program (SEAP) to leverage Samsung’s extensive global sales and marketing network.
By adding support for the Android mobile operating system, Glooko now provides a diabetes management platform t hat is accessible to tens of m illions of people with diabetes. According to a recent report by c om S core on key trends in t he smartphone industry , Android is ranked as the number one smartphone platform with 52% market share in the US and 65% in Europe . Wi th the addition of Android support , Glooko enable s people with diabetes to easily collect, view and share their blood glucose readings on many Android phones including Samsung, HTC and LG models . For professionals and disease management staffs , the Glooko diabetes management system offers the analytical tools that can enable consistent care across their diabetes patient s along with an improved ability to advise their patients remotely . By using Glooko , health systems aim to create a higher level of adheren ce to treatment plans among their diabetes population.
The Glooko Diabetes Management System for Android runs on devices using the Android operating system , including phones such as the industry leading Samsung Galaxy SIII and S4. Using Glooko’s mobile application, these devices can currently download glucose data from dozens of compatible meters, including but not limite d to Roche’s ACCU – CHEK ® Aviva (Black) , Abbott’s FreeStyle Lite ® , and Lifescan’s OneTouch ® Ultra ® 2 , OneTouch ® UltraLink ® , and a variety of Nipro meters. Glooko expects to add even more devices soon, including additional glucose meters and eventually insulin pumps.
To learn more about Glooko, including a full list of compatible devices, visit https://glooko.com
About Glooko
Glooko™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. Glooko’s products – the Glooko mobile app and MeterSync Cable for iOS and Android – enable people with diabetes to easily collect, view and share the information needed to help them successfully control their blood glucose readings. It has been hailed by users and industry influencers for its ease of use and ability to deliver context t o daily data collected by people with diabetes on both a mobile and web – based platform. The company was founded in 2010 by technologist Yogen Dalal and mobile and web app developer, Sundeep Madra. Endocrinologist Michael S. Greenfield, M.D., is chief medic al officer. The company’s first generation product received FDA 510(k) clearance in December 2012. Many on the Glooko team , including the founders , have a personal connection to diabetes. Glooko is backed by several Silicon Valley innovators including form er Facebook, Apple and Cisco executives. Together they are committed to helping people with diabetes live their lives , while effortlessly managing their diabetes.